Purchase Order N0025919P0418
Award Date 9/30/19
Potential Completion Date 9/3/24
Potential Value $104K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Cerus Corporation received a firm fixed-price purchase order from the Defense Health Agency (DHA) on August 27, 2021, for INTERCEPT Platelet Set-Small units (Part No. INT2130B), with a ceiling value of $218,371.20 and an ultimate completion date of October 1, 2024. The contract was awarded without a set-aside designation and will be performed in Concord, California, where Cerus maintains its headquarters. Cerus Corporation specializes in blood safety technologies and pathogen reduction...
- The Defense Health Agency awarded a firm fixed-price purchase order to Cerus Corporation for $367.1K on October 1, 2025, with an ultimate completion date of September 30, 2030. The contract covers Cerus Intercept Platelet Processing Sets, specialized medical equipment used in blood pathogen reduction treatment. Cerus Corporation, a biomedical products manufacturer headquartered in Concord, California, specializes in blood safety technologies and the proprietary INTERCEPT Blood System, which uses...
- The Defense Health Agency (DOD) awarded a $367,504.80 firm fixed price purchase order to Cerus Corporation to provide INTERCEPT Platelet Processing and Service Maintenance for the Walter Reed National Military Center in Bethesda, Maryland from January 13, 2022 through January 31, 2027. Cerus Corporation will supply its INTERCEPT Blood System for platelets, which utilizes ultraviolet light and riboflavin to inactivate pathogens in platelet components during the collection and storage process,...
- The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
- This firm-fixed-price purchase order was awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company, for the provision of INTERCEPT Platelet Processing Sets. Valued at $137,664.00, the contract does not have a set-aside designation. Cerus has received over 20 previous prime federal contract awards from agencies including the DoD, VA, and HHS to provide pathogen reduction technologies, equipment, and associated services to support military and veterans' medical...
- The Defense Health Agency (DHA) awarded a firm fixed-price purchase order to Cerus Corporation on October 1, 2024, for INTERCEPT Platelet Processing Sets to support the Naval Base San Diego Laboratory. The contract carries a ceiling value of $232,128.00 and extends through September 30, 2027. No set-aside designation was used in this award. Cerus Corporation, headquartered in Concord, California, is a biomedical products manufacturer specializing in blood safety technologies and pathogen...
- The Defense Health Agency awarded a $258.2K firm fixed-price purchase order to Cerus Corporation for Intercept Platelet Pathogen Reduction Sets at Tripler Army Medical Center in Hawaii. The contract, awarded October 1, 2021, with an ultimate completion date of September 30, 2025, represents a sole-source procurement under FAR 13.106-1(b)(1)(i), as Cerus Corporation is the only provider capable of meeting the government's specialized requirements. The Intercept system utilizes riboflavin and...
- This federal contract award, valued at $127,680.00, was issued by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the provision of INTERCEPT Platelet Processing Sets, which use Cerus' proprietary INTERCEPT Blood System to inactivate pathogens in blood components. The INTERCEPT system employs riboflavin and ultraviolet light to reduce the risk of transfusion-transmitted infections. This contract does...
- The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
- The Defense Health Agency awarded a $193,882 firm fixed-price purchase order to Cerus Corporation on January 14, 2025, for INTERCEPT Platelet Processing Sets and service maintenance in support of the Blood Bank Department at Naval Hospital Guam in Agana Heights, Guam. The contract, which extends through September 30, 2027, procures INTERCEPT Platelet Small Volume Processing Sets, INTERCEPT Platelet Processing Sets with Dual Storage Containers, and annual maintenance services for two...